ScripThe former CEOs of Galena Biopharma Inc. and ImmunoCellular Therapeutics Ltd. received the harshest penalties in Securities and Exchange Commission enforcement actions against four biopharma c
ScripEli Lilly & Co. is cutting costs by chopping 3,500 jobs from its payroll and will spend the $500m in annual savings on activities that will help the company grow its revenue – research and developme
Pink SheetIt’s early days yet, but checkpoint immunotherapies have the potential to jump-start the high-risk, high reward glioblastoma drug development space, which has been prone to many a setback, the latest
ScripThe bad news about the rapid rise in biotechnology company valuations? It will end eventually. The good news? While initial public offerings may no longer be an option for some pre-commercial companie